These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 34093445)

  • 21. Exceptional increase in somatostatin receptor expression in pancreatic neuroendocrine tumour, visualised with (68)Ga-DOTATOC PET.
    Henze M; Schuhmacher J; Dimitrakopoulou-Strauss A; Strauss LG; Mäcke HR; Eisenhut M; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2004 Mar; 31(3):466. PubMed ID: 14730407
    [No Abstract]   [Full Text] [Related]  

  • 22. Pasireotide in the treatment of neuroendocrine tumors: a review of the literature.
    Vitale G; Dicitore A; Sciammarella C; Di Molfetta S; Rubino M; Faggiano A; Colao A
    Endocr Relat Cancer; 2018 Jun; 25(6):R351-R364. PubMed ID: 29643113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
    Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
    Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors.
    Narayanan S; Kunz PL
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):163-77. PubMed ID: 26614375
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT data in patients with pancreatic neuroendocrine neoplasm.
    Kaemmerer D; Wirtz RM; Fischer EK; Hommann M; Sänger J; Prasad V; Specht E; Baum RP; Schulz S; Lupp A
    Pancreas; 2015 May; 44(4):648-54. PubMed ID: 25872131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptide Receptor Radionuclide Therapy with
    Cullinane C; Jeffery CM; Roselt PD; van Dam EM; Jackson S; Kuan K; Jackson P; Binns D; van Zuylekom J; Harris MJ; Hicks RJ; Donnelly PS
    J Nucl Med; 2020 Dec; 61(12):1800-1805. PubMed ID: 32414949
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
    Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
    Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. State of the Art and Recent Developments of Radiopharmaceuticals for Pancreatic Neuroendocrine Tumors Imaging.
    Carollo A; Papi S; Grana CM; Mansi L; Chinol M
    Curr Radiopharm; 2019; 12(2):107-125. PubMed ID: 30843499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does combination of "cold" and "hot" somatostatin analogs prolong survival of patients with neuroendocrine neoplasms?
    Sowa-Staszczak A; Stefanska A; Chrapczynski P; Trofimiuk-Müldner M; Szura M; Hubalewska-Dydejczyk A
    Endocr J; 2017 Feb; 64(2):171-177. PubMed ID: 27853048
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors.
    Song KB; Kim SC; Kim JH; Seo DW; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
    Pancreas; 2016 Feb; 45(2):187-92. PubMed ID: 26474434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: somatostatin receptor imaging with (111)In-pentetreotide.
    Kwekkeboom DJ; Krenning EP; Scheidhauer K; Lewington V; Lebtahi R; Grossman A; Vitek P; Sundin A; Plöckinger U; ;
    Neuroendocrinology; 2009; 90(2):184-9. PubMed ID: 19713709
    [No Abstract]   [Full Text] [Related]  

  • 32. Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors.
    Couvelard A; Pélaprat D; Dokmak S; Sauvanet A; Voisin T; Couvineau A; Ruszniewski P
    Pancreas; 2017; 46(5):631-638. PubMed ID: 28375946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy with radiolabeled somatostatin peptide analogs for metastatic neuroendocrine tumors.
    Bushnell D
    J Gastrointest Surg; 2006 Mar; 10(3):335-6. PubMed ID: 16622984
    [No Abstract]   [Full Text] [Related]  

  • 34. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature.
    Johnbeck CB; Knigge U; Kjær A
    Future Oncol; 2014 Nov; 10(14):2259-77. PubMed ID: 25471038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Endoscopic diagnosis and treatment of pancreatic neuroendocrine tumors.
    Rustagi T; Farrell JJ
    J Clin Gastroenterol; 2014; 48(10):837-44. PubMed ID: 24828360
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Somatostatin receptor targeting for tumor imaging and therapy.
    Grötzinger C; Wiedenmann B
    Ann N Y Acad Sci; 2004 Apr; 1014():258-64. PubMed ID: 15153442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Illuminating somatostatin analog action at neuroendocrine tumor receptors.
    Reubi JC; Schonbrunn A
    Trends Pharmacol Sci; 2013 Dec; 34(12):676-88. PubMed ID: 24183675
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.
    Herrera-Martínez AD; Gahete MD; Pedraza-Arevalo S; Sánchez-Sánchez R; Ortega-Salas R; Serrano-Blanch R; Luque RM; Gálvez-Moreno MA; Castaño JP
    Endocrine; 2018 Feb; 59(2):426-437. PubMed ID: 29196939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Function and expression of somatostatin receptors of the endocrine pancreas.
    Strowski MZ; Blake AD
    Mol Cell Endocrinol; 2008 May; 286(1-2):169-79. PubMed ID: 18375050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.